U.S. Food And Drug Association Approves Repatha For High Cholesterol

Being considered for the last two months, Repatha has won federal approval for use against high cholesterol. For patients with low-density lipoprotein (LDL) cholesterol, the drug Repatha might be suitable. John Jenkins, M.D., director of the Office of New Drugs, Center for Drug Evaluation and Research spoke favorably of the drug’s specific use.

“Repatha provides another treatment option in this new class of drugs for patients with familial hypercholesterolemia or with known cardiovascular disease who have not been able to lower their LDL cholesterol enough with statins.”

The drug works by increasing the number of liver receptors which remove LDL cholesterol.

“Participants taking Repatha had an average reduction in LDL cholesterol of approximately 60 percent, compared to placebo.”

As Repatha has such dramatic results, demand is likely to be high due to the potential benefits of increasing the quality and length of life for those suffering from conditions not responding to diet and Statins to lower their cholesterol.

The origin of Repatha came from observations of people with liver mutations — particularly the African-American Population — with the results that the two percent of African-Americans with the mutation naturally had an 80 percent lifelong reduction in LDL-C levels.

Repatha has made the list for one of the top ten medical inventions of all time.